inhaled corticosteroids - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

hospitalization or death 0.81 [0.58, 1.13]< 10%1 study (1/-)89.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.16 [0.03, 0.74]< 10%1 study (1/-)99.0 %highnot evaluable lowimportant-
clinical improvement 1.21 [1.08, 1.36]> 10%2 studies (2/-)100.0 %highnot evaluable lowimportant-
clinical improvement (14-day) 1.50 [0.69, 3.24]> 10%1 study (1/-)84.7 %highnot evaluable lowimportant-
mechanical ventilation 1.02 [0.45, 2.33]< 10%1 study (1/-)48.1 %some concernnot evaluable moderateimportant-
ICU admission 0.54 [0.24, 1.21]< 10%1 study (1/-)93.2 %some concernnot evaluable moderatenon important-
recovery 1.21 [1.08, 1.36]> 10%1 study (1/-)99.9 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.